Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 November 2021 | Story Dr Nitha Ramnath | Photo Supplied


“Running provides me with a platform to reach others, to bring hope, to make people realise that anything is possible if you are prepared to work hard for it,” says Louzanne Coetzee, our very own home-grown all-round achiever, who is fun-loving, relatable, and inspiring. A South African para-athlete, Coetzee was born blind as a result of a hereditary condition called Leber congenital amaurosis, and competes in the T11 disability class for athletes with the highest level of visual impairment. Coetzee enjoys an integrated life, with an interest in baking, watching movies, walking and hiking, cycling, being part of a church band, public speaking, coupled with some artistic hobbies.

Our podcast guest

Coetzee competed at the 2020 Tokyo Paralympic Games this year, where she won a silver medal in the 1 500 m final alongside her guide Erasmus Badenshorst, setting a new African record of 4:40.96. She also competed in the women’s mixed class marathon (T11 and T12 for the visually impaired) with her guide Claus Kempen, improving the world record by 1 min 42 sec and her personal best from 3:13:41 to 3:11:13. 

In 2018, Coetzee competed in three events at the Para Athletics event in Berlin, Germany – the 800 m, 1 500 m, and 5 000 m. She set a new African record in the T11 800 m race, taking the silver medal, as well as a bronze for the 1 500 m race. In 2018, Coetzee also broke the 5 000 m (women) world record in her disability class, while in the same year she became the first visually impaired athlete to compete at the World University Cross Country Championships in Switzerland. 
Coetzee set a new world record in the 5 000 m T11 category for the first time at the Nedbank National Championships for the Physically Disabled in March 2016. Moreover, with her performance of 19:17.06, Coetzee shattered the Lithuanian athlete Sigita Markeviciene’s 16-year record of 20:05.81, set at the 2000 Paralympics in Sydney. Coetzee became the first totally blind female to clock sub-20 minutes in the 5 000 m.

Her involvement in her society stretches beyond sports, and as a student, she formed part of the University of the Free State Student Representative Council. She was also an athlete representative on the Free State Academy of Sport’s executive committee.

In 2014, she became the first visually impaired student to be elected to the UFS Student Representative Council (SRC), with the portfolio Student Accessibility. From 2015 to 2017, she was a research assistant in the Institute for Reconciliation and Social Justice at the UFS, and in 2016 she also acted as junior lecturer in a computer module for students with visual impairments. From 2017 to 2018, she was Residence Head of Arista Ladies City Residence, and she is currently the Residence Head of Akasia Residence at the UFS.  

Coetzee boasts several accolades from the UFS. She was named the 2014 Senior Sportswoman of the Year by the Free State Sport Association for the Physically Disabled (FSSAPD). In 2017, she and her guide Khothatso Mokone received a Special Award for Disabled Sport at the KovsieSport Awards. In 2018, she won the Free State Sports Star Award, and was named Sports Star of the Year (period June 2018 to April 2019) by the Free State Sport Association for the Physically Disabled. 

Coetzee’s academic qualifications include a BA and BAHons in Integrated and Corporative Marketing Communication, and an MA in Social Cohesion and Reconciliation – all from the University of the Free State. 
Listen to the podcast  below

François van Schalkwyk and Keenan Carelse, UFS alumni leading the university’s United Kingdom Alumni Chapter, have put their voices together to produce and direct the podcast series.  Intended to reconnect alumni with the university and their university experience, the podcasts will be featured on the first Monday of every month, ending in November 2021.  Our featured alumni share and reflect on their experiences at the UFS, how it has shaped their lives, and relate why their ongoing association with the UFS is still relevant and important. The podcasts are authentic conversations – they provide an opportunity for the university to understand and learn about the experiences of its alumni and to celebrate the diversity and touchpoints that unite them. 

For further information regarding the podcast series, or to propose other alumni guests, please email us at alumnipodcast@ufs.ac.za 

For all Voices from the Free State podcasts, click here 
    

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept